Oncotype Dx Colon Cancer Assay

High Quality Content by WIKIPEDIA articles! The Oncotype DX Colon Cancer Assay, developed by Genomic Health, is a genomic test that has been clinically available for patients with newly diagnosed stage II colon cancer since January 2010. The test is a validated diagnostic assay based on an individual patient\'s colon tumor expression of 12 genes, which quantifies the likelihood of recurrence in stage II colon cancer following surgery. The result from the assay is a continuous Recurrence Score(r) value from 0 to 100 that corresponds to a specific likelihood of colon cancer recurrence 3 years after surgery. A lower score corresponds to a lower risk of recurrence, and a higher score corresponds to a higher risk of recurrence. The Recurrence Score result provides additional information on recurrence risk beyond traditional clinical and pathological characteristics such as tumor stage (T-stage), mismatch repair (MMR) status, number of lymph nodes examined, tumor grade and lymphovascular invasion . The Oncotype DX Colon Cancer Assay has the greatest utility for the stage II colon cancer patients with T3 and MMR proficient tumors. Dannoe izdanie predstavlyaet soboj kompilyatsiyu svedenij, nahodyaschihsya v svobodnom dostupe v srede Internet v tselom, i v informatsionnom setevom resurse "Vikipediya" v chastnosti. Sobrannaya po chastotnym zaprosam ukazannoj tematiki, dannaya kompilyatsiya postroena po printsipu podbora blizkih informatsionnyh ssylok, ne imeet samostoyatelnogo syuzheta, ne soderzhit nikakih analiticheskih materialov, vyvodov, otsenok moralnogo, eticheskogo, politicheskogo, religioznogo i mirovozzrencheskogo haraktera v otnoshenii glavnoj tematiki, predstavlyaya soboj isklyuchitelno faktologicheskij material. This book was created using print-on-demand technology.